40 results about "Colicin" patented technology

Chimeric proteins are expressed, secreted or released by a bacterium to immunize against or treat a parasite, infectious disease or malignancy. The delivery vector may also be attenuated, non-pathogenic, low pathogenic, or a probiotic bacterium. The chimeric proteins include chimeras of, e.g., phage coat and/or colicin proteins, bacterial toxins and/or enzymes, autotransporter peptides, lytic peptides, multimerization domains, and/or membrane transducing (ferry) peptides. The active portion of the immunogenic chimeric proteins can include antigens against a wide range of parasites and infectious agents, cancers, Alzheimer's and Huntington's diseases, and have enhanced activity when secreted or released by the bacteria, and/or have direct anti-parasite or infectious agent activity. The activity of the secreted proteins is further increased by co-expression of a protease inhibitor that prevents degradation of the effector peptides. Addition of an antibody binding or antibody-degrading protein further prevents the premature elimination of the vector and enhances the immune response.

The present invention provides one kind of gene, recombinant plasmid and polypeptide of EB virus resisting tumor polypeptide. The coding inducing polypeptide gene and coliform group gene are connected via operation to obtain polynucleotide sequence expressing recombinant antitumor polypeptide. The nucleotide sequence of the coding inducing polypeptide is inserted into coliform group gene by means of double strand oligomeric nucleotide point mutation technology to form the said recombinant plasmid. The obtained recombinant plasmid is transfected into engineering colibacillus TG1 to obtain engineering bacillus cell capable of generating recombinant antitumor polypeptide; and through mass proliferation, centrifugal precipitation and other steps, recombinant antitumor polypeptide is obtained. The antitumor polypeptide has specific targeting property, high efficiency of killing solid tumor, no attack to health cell, low toxicity and less negative reaction.

The invention discloses a midget anti drug-tolerance staphylococcus aureus polypeptide comprised of passage structure domain to form ion channel colicine and staphylococcus aureu pheromone, as well as opposite coded nucleotide sequence and recombination plasmid contained said sequence. Wherein, the plupeptide can not induce bacteria to generate trsditional drug-tolerance by the mechnism that it forms directly ion channel on cell film of target cell to kill bacteria. This invention has more single antimicrobial spectrum without effect to Gram-negative bacteria of escherichia coli, shows at least 500 times effect to pheneazonecillin, and can be used as synergist to beta-lactam antibiotics.

An antivirus engineered polypeptide is composed of the polypeptide able to specifically bind coated virus antigen or receptor and the colicin able to form ion channel or its channel structure domain. It has two molecular structures divided according to different links between amino terminal and carboxyl terminal. Different engineered polypeptides for different viruses can be prepared by binding the colicin or its channel structure domain with the above-mentioned different polypeptide. Its advantage is sure effect on killing viruses.

The present invention provides a fusion polypeptide against EB virus-induced tumor, which comprises an antibody or a mimetic antibody against EB virus and an ion channel forming colicin selected form E1, Ia, Ib, A, B, N and their mutants. The present invention also provides a colicin Ia mutant, which comprises mutations of G11A, H22G, A26G, V31L, and H40D. The present invention also provides a gene, vector, preparation method and use of the fusion polypeptide, and provides a gene and use of the mutant.

The present invention discloses a novel anti-crop-epiphyte polypeptide and a preparation method thereof. A recombined anti-crop-epiphyte polypeptide is formed by linking gene which codes white candida pheromone and the gene which codes colicin. Compared with the prior anti-crop-epiphyte medicine, the novel anti-crop-epiphyte polypeptide of the present invention has the advantages that the novel anti-crop-epiphyte polypeptide directly forms ionic passage at epiphytic cell membrane to kill the epiphyte, so the killing efficiency is thousands times stronger than the prior anti-crop-epiphyte medicine; the epiphyte can hardly amend the geometrical damage at the cell membrane caused by the polypeptide by the mutation-expression form, so the polypeptide can not induce the epiphyte producing the traditional drug resistance; the polypeptide is a biological preparation and has target killing towards the epiphyte, so the novel anti-crop-epiphyte polypeptide does not have the toxic and side effects of the prior anti-crop-epiphyte medicine.

The Invention relates to materials and methods for the treatment of conditions associated with bacterial biofilms, intracellular bacterial infections and/or adherent-invasive Escherichia coli infections, including Crohns' disease. In particular, the invention relates to the use of colicins and bacteria producing colicins, for the treatment of such conditions.

The present invention relates to one kind of enveloped virus resisting polypeptide and its encoding nucleotide and amino acid sequence. Colicin capable of forming ion channel or its aquatic porous channel structural domain is made to combine with polypeptide capable of being combined specifically with target virus envelope antigen to form engineering polypeptide. Inside the engineering polypeptide, ScFv antigen combining area capable of being combined specifically with target virus envelope antigen induces the colicin water soluble porous channel structural domain to near target virus envelope, the colicin water soluble porous channel structural domain then forms the ion channel on the envelope to destroy the completeness of the envelope to leak or expose virus RNA and kill virosome. The antiviral engineering polypeptide kills selected virosome without injuring host cell, being superior to traditional antiviral medicines.

A miniature polypeptide resisting to EB virus tumor, its gene and its recombinant plasmid are disclosed. Its preparing process includes linking the gene for coding and leading peptide with the plasmid carrying the colicin ion channel structure domain gene, transferring engineering bacteria for amplifying, and separating and purifying by His-tag column. It can be used to kill tumor cells.

The present invention relates to two recombinant colicin expression systems, one utilizing a yeast expression system that produces a protein that is inexpensive to purify, and the other utilizing a plasmid expression system to be used as a probiotic culture. The recombinant colicins provide effective alternatives to conventional antibiotics and may be used to improve the efficiency of pork production, and the safety of its products.

The invention provides a method of preventing or reducing contamination of an object such as food with enterohaemorrhagic E. coli (EHEC), comprising contacting said object with colicin M or a derivative thereof.

An artificially recombined engineering polypeptide resisting against staphylococei is composed of the staphylococcus' signal transfer polypeptide and the colicin able to form ion channel or its water pore canal structure domain. Its preparing process includes using point mutation to insert the staphylococcus' signal transfer polypeptide gene into the site chosen by colicin gene loaded in engineering plasmid and transfecting the mutative plasmid to engineering bacteria. Its advantages are strong antibacterial power to staphylococei, and not generating resistance easily by staphylococei.

The invention relates to a recombinant lactobacillus plantarum capable of secreting colicins V and a preparation method thereof, belonging to the field of microbe molecule biology. The recombinant lactobacillus plantarum disclosed by the invention carries a free expression vector containing a pediocin PA-1 leading peptide-mature colicin V fused gene. The recombinant lactobacillus plantarum is prepared through connecting a pediocin PA-1 leading peptide-mature colicin V peptide fused gene to an expression vector, transferring a connecting product to lactococcus lactis by using an electrotransformation method, extracting a recombinant plasmid, and transferring the recombinant plasmid to lactobacillus plantarum BM-1 through electrotransformation. The recombinant lactobacillus plantarum disclosed by the invention can simultaneously secrete pediocin PA-1 and colicin V, and has a good inhibitory effect on colicins and listeria monocytogenes pathogenic bacteria; after being eaten by animals, the recombinant lactobacillus plantarum does not produce toxic and side effects and residues, so that the recombinant lactobacillus plantarum has no threat to the environment and food security, therefore, the recombinant lactobacillus plantarum has a good application prospect in the fields of feed industry and food industry.

The present invention discloses an anti-cancer peptide with an amino acid sequence of SEQ ID NO.1, the expression body, the preparation method and the application in preparing anti-cancer drugs. The method comprises: a. the plasmid pTWIN2 carrier is used; a 13-peptide containing RGD sequence of OPN is inserted into the viscous end after treatment of endonuclease BspQI; the homocysteine TGC is added in designing of primer; the primer and the carrier after treatment of endonuclease are connected for a night at a temperature of 16 DEG C according to a ratio of 1 to 10 (molar ratio), through the denaturalization and annealing method of the primer; the recombinant plasmid pTWIN2-RGD can be prepared; b. the recombinant plasmid is digested by colicin and transferred into the colicin or Escherichia to induce and collect purified protein. The anti-cancer peptide of the present invention has good anti-cancer activity and is easy for synthesis.

Described herein is the isolation of colicin-producing strains of E. coli for use as probiotic treatments for the prevention of E. coli K88+diarrhea. These strains of E. coli, designated as UM-17, and UM-19, express a filament and produce colicin but produce no compounds toxic to the host animal and as such inhibit the growth of E. coli K88+.